Cardiol Therapeutics (TSE:CRDL) Stock Price Down 4.9% – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL) shares fell 4.9% during trading on Wednesday . The stock traded as low as C$1.53 and last traded at C$1.55. 47,095 shares were traded during mid-day trading, a decline of 56% from the average session volume of 107,183 shares. The stock had previously closed at C$1.63.

Cardiol Therapeutics Stock Performance

The company has a market cap of C$180.98 million, a P/E ratio of -4.03 and a beta of 0.24. The company has a quick ratio of 6.84, a current ratio of 4.39 and a debt-to-equity ratio of 0.48. The business has a fifty day simple moving average of C$1.84 and a two-hundred day simple moving average of C$1.55.

Cardiol Therapeutics (TSE:CRDL) last issued its quarterly earnings results on Monday, May 11th. The company reported C($0.10) earnings per share for the quarter. On average, sell-side analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.